The Modern Data Company and Thoughtworks Form Strategic Alliance to Accelerate Data Mesh Implementations and AI Initiatives
18.7.2023 13:12:00 EEST | Business Wire | Press release
The Modern Data Company, pioneers of the world's first data operating system, DataOS®, is thrilled to announce a strategic partnership with renowned global technology consultancy, Thoughtworks (NASDAQ: TWKS). This groundbreaking collaboration is set to reimagine data operations and accelerate the adoption of Data Products, Data Mesh, and AI initiatives across a wide range of industries.
Harnessing its rich expertise in data strategies, Thoughtworks has led numerous successful data transformation initiatives. The pairing of this experience with the technologically advanced Modern Data Company’s DataOS Platform--designed to streamline creation and management of Data Products, the key ingredients for a Data Mesh implementation--forms the backbone of this partnership. This collaborative alliance is set to unlock the full potential of organizational data, spearhead innovation, and pave the way for successful data modernization initiatives.
“The partnership between Modern and Thoughtworks marks a significant step as we transform how data is implemented and applied across an organization. We're changing the game by moving from traditional tables to a Data Product approach, and this collaboration significantly advances our shared vision. At The Modern Data Company, we firmly believe that the future lies in viewing and treating data as a product. This reimagining enables rapid, comprehensive creation and management of data, accelerating innovation and unlocking its full potential,” said Srujan Akula, CEO, The Modern Data Company. “By pairing Thoughtworks' profound expertise in data strategies with our innovative DataOS platform, we're poised to bring about a transformative shift in how organizations leverage their data.”
DataOS is an integrated platform that simplifies and expedites data development cycles. It equips teams with the comprehensive tools to easily build, manage, deploy, and iterate on their data products, all while ensuring seamless compatibility with the existing data infrastructure. This enables businesses to use their data assets without interruptions, maximizing derived value.
“The Modern Data Company and Thoughtworks have partnered to combine the world’s first data operating system, Modern’s DataOS, and Thoughtworks’ world-class data engineering and AI practices to help you thrive in today’s data-driven economy,” said John Spens, VP Data & AI Service Line, Thoughtworks. “Accelerate insights to drive your business by delivering transparent, trustworthy and accessible data efficiently and well.”
Stay tuned for more updates on this strategic partnership. For more information about The Modern Data Company and Thoughtworks, please visit their websites at https://TheModernDataCompany.com and https://Thoughtworks.com, respectively.
About The Modern Data Company:
The Modern Data Company offers comprehensive data management products. Our flagship product, DataOS®, is a data operating system pioneered to build comprehensive data products and accelerate the adoption of data mesh implementations so that organizations become truly data-driven and AI-ready.
See The Modern Data Company at CDOIQ 2023 in Cambridge, MA. at Booth #29 to learn more about data products and data mesh implementations.
About Thoughtworks
Thoughtworks is a global technology consultancy with more than 12,500 employees in 50 offices across 18 countries. It integrates strategy, design, and software engineering services for clients ranging from global Fortune 500 enterprises to digital natives and digital scaleups in industries like automotive, retail, financial services, healthcare, and the public sector. Founded in 1993, Thoughtworks is headquartered in Chicago.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230718888038/en/
Contact information
Press Contact:
Emanuel Younanzadeh
VP Marketing
The Modern Data Company
emanuel@tmdc.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom